Myeloproliferative Neoplasm-Blast Phase (MPN- BP) has poor outcome with overall survival (OS) <6 months (mo), and limited responses to intensive chemotherapy. Venetoclax (VEN) plus hypometilating agents, effective in unfit or relapsed/refractory de-novo AML, is increasingly considered for MPN-BP. However, MPN-BP’s distinct molecular profile may not be adequately captured by current risk models (ELN24/mPRS, ELN24-refined). Aim: To define a prognostic risk profile using clinical data from ENABLE, a phase 2 trial exploring VEN and decitabine in MPN-BP
B07 | Molecular risk profiling in myeloproliferative neoplasms blast phase treated with venetoclax and decitabine: a three-gene score for survival prediction / Crupi, F.. - In: HAEMATOLOGICA. - ISSN 1592-8721. - ELETTRONICO. - 111:(2026), pp. 0-0. [10.3324/haematol.2026.s1.15]
B07 | Molecular risk profiling in myeloproliferative neoplasms blast phase treated with venetoclax and decitabine: a three-gene score for survival prediction
Crupi Francesca;A. M. Vannucchi
2026
Abstract
Myeloproliferative Neoplasm-Blast Phase (MPN- BP) has poor outcome with overall survival (OS) <6 months (mo), and limited responses to intensive chemotherapy. Venetoclax (VEN) plus hypometilating agents, effective in unfit or relapsed/refractory de-novo AML, is increasingly considered for MPN-BP. However, MPN-BP’s distinct molecular profile may not be adequately captured by current risk models (ELN24/mPRS, ELN24-refined). Aim: To define a prognostic risk profile using clinical data from ENABLE, a phase 2 trial exploring VEN and decitabine in MPN-BP| File | Dimensione | Formato | |
|---|---|---|---|
|
13210-Article Text-90435-1-10-20260304.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
506.94 kB
Formato
Adobe PDF
|
506.94 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.



